BI-1206 waa musharraxa dawada hogaanka ah ee BioInvent waxaana hadda lagu baarayaa laba tijaabo oo waji 1/2 ah. Mid ayaa qiimeynaysa isku-dhafka BI-1206 ee leh rituximab ee daawaynta Non-Hodgkin lymfoma, oo ay ku jiraan bukaanada qaba FL, MCL iyo lymphoma aagga marginal (MZL) kuwaas oo dib u soo noqday ama ka soo horjeeda rituximab. Tijaabada Wajiga labaad ee 1/2 ayaa baaraya BI-1206 marka lagu daro daawaynta ka hortagga PD1 Keytruda® (pembrolizumab) ee burooyinka adag.
Dr. Wei-Wu He, Guddoomiyaha CASI, iyo maamulaha guud ayaa faallo ka bixiyay, "BioInvent waxay sii waddaa inay horumar ka samayso qaabka horumarinta iyo sharciyeynta BI-1206. Oggolaanshaha CTA ee Shiinaha Diseembar 2021 iyo Naqshadeynta Dawooyinka Agoonta ee FDA ee dhowaan waxay muujineysaa awoodda xoogga leh ee ka hortagga heerka koowaad. CASI waxay leedahay xuquuqaha ganacsi ee Shiinaha ee BI-1026, kooxdeenu waxay isu diyaarinaysaa daraasadda caafimaad ee Shiinaha. CASI iyo BioInvent waa shuraakooyin aan kala go 'lahayn waxayna leeyihiin hadaf guud si ay uga faa'iidaystaan bukaanada leh tignoolajiyada cusub ee dawooyinka."
MAXAA LAGU QAADAYAA MAQAALKAN:
- One is evaluating the BI-1206 combination with rituximab for the treatment of Non-Hodgkin lymphoma, which includes patients with FL, MCL and marginal zone lymphoma (MZL) who have relapsed or are refractory to rituximab.
- The CTA approval in China in December 2021 and the recent FDA Orphan Drug Designation demonstrate the strong potential of this first-in-class antibody.
- A second Phase 1/2 trial is investigating BI-1206 in combination with anti-PD1 therapy Keytruda® (pembrolizumab) in solid tumors.
